News

Probiodrug and Crossbeta Biosciences are extending a partnership that Probiodrug believes will help it continue developing a potential Alzheimer’s therapy. Under the partnership, established in 2016, the companies are using a proprietary Crossbeta technology to try to create biomarkers specific to Alzheimer’s as opposed to   neurodegenerative diseases in general.

Trace levels of lithium in drinking water reduce Alzheimer’s death rates in addition to two risk factors for the disease — obesity and Type 2 diabetes, according to a study. The Canadian study dealt with lithium in Texas’s drinking water. Researchers published their work in the Journal of Alzheimer’s…

The number of Americans with Alzheimer’s disease or mild cognitive impairment, which can be a precursor to the disease, will more than double to 15 million by 2060, according to a new UCLA Fielding School of Public Health study. With funding from the…

Massachusetts Institute of Technology researchers have found that Alzheimer’s disease causes microglia — the immune cells that normally protect brain cells from damage — to change their behavior and instead promote a pro-inflammatory immune response. Their study, “Temporal Tracking of Microglia Activation in Neurodegeneration at Single-Cell Resolution,” appeared in…

Changes in brain cells known as astrocytes mirror transformations in Alzheimer’s disease, and may contribute to patients’ nerve cell degeneration, a Finnish study reports. It is the first time that research has shown that astrocytes may contribute to Alzheimer’s. The University of Eastern Finland team published their work, “PSEN1 Mutant iPSC-Derived Model…

Researchers found that the combination of titanate, a nanoparticle that can penetrate the brain-blood barrier, and cerebrolysin, used in some parts of the world to treat problems with cognition, had superior neuroprotective effects in an animal model of Alzheimer’s disease than cerebrolysin alone. The study, “Co-Administration of TiO2 Nanowired…

U.S. Postmaster General Megan J. Brennan has dedicated a new semipostal stamp to fund research to find a cure for Alzheimer’s disease. Under the Semipostal Authorization Act, five semipostal fundraising stamps will be issued over the next 10 years, with each one to be sold for no…

Immungenetics AG is conducting a Phase 2 proof-of-concept clinical trial to investigate whether thiethylperazine — a treatment for nausea and vomiting in use since the 1960s — might help people with Alzheimer’s disease by working to slow or stop the early events that underlie disease progression. Thiethylperazine, sold…

Researchers in Wisconsin are looking for veterans with a family history of Alzheimer’s disease to determine whether fish oil can stop brain damage during the disorder’s early stages. “We know fish oil has beneficial effects on heart health,” Dr. Cindy Carlsson, the trial’s leading investigator and a researcher at the…

TauRx Therapeutics’ experimental Alzheimer’s disease treatment LMTX may slow cognitive decline in patients at doses as low as 4 mg — but only when used without other Alzheimer’s drugs — a recent report shows. The findings support data from an earlier Phase 3 trial, which also studied much higher doses…